Drugs / WTX221
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05800041 | Apr → Jul 2023 | gout | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WTX221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05800041 ↗ |
| Modality | Protein / enzyme biologic | “WTX221 is made of urate oxidase(UOX) molecules conjugated on the surface of Red blood cells(RBCs)” NCT05800041 ↗ |
| Route | Other | “WTX221 infusion once every 30 days for two doses in total” NCT05800041 ↗ |